Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. SanBio Company Limited
  6. News
  7. Summary
    4592   JP3336750009

SANBIO COMPANY LIMITED

(4592)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

SanBio : Presentation for Financial Results for the 2nd Quarter of the Fiscal Year Ending January 31, 2022

09/16/2021 | 05:02am EDT

Financial Results for the Second Quarter of the Fiscal Year Ending January 31, 2022

September 16, 2021

SanBio Company Limited

(TSE Mothers: 4592)

Table of Contents

  1. Financial Results
  2. SB623 Approval in Japan and Subsequent Developments
  3. Q&A

©2021 SanBio Company Limited

1

1. Financial Results

©2021 SanBio Company Limited

2

Consolidated Income Statement

R&D expenses increased due to higher manufacturing-related expenses in preparation for

approval filing of SB623 for chronic effects of traumatic brain injury (TBI program)

Q2 FY2021.1

Q2 FY2022.1

FY2022.1

Results

Results

(B)-(A)

Forecast

(A)

(B)

Unit: Million yen

Revenue

-

-

-

-

R&D expenses

1,798

2,251

+453

3,820

Operating expenses

2,570

3,052

+482

5,786

Operating income

-2,570

-3,052

-482

-5,786

Net income

-3,207

-2,134

+1,073

-5,877

Yen/USD exchange

108.45

108.79

-

110.00

rate

©2021 SanBio Company Limited

3

Consolidated Balance Sheet

Despite declines in cash & cash equivalents and in net assets,

SanBio maintained a stable financial position

As of January 31, 2021

As of July 31, 2021

(B)-(A)

(A)

(B)

Unit: Million yen

Cash & cash

12,480

8,794

-3,686

equivalents

Supplies

444

453

+9

Current assets

13,131

9,515

-3,616

Non-current assets

211

193

-18

Total assets

13,343

9,709

-3,634

Current liabilities

2,468

1,857

-611

Non-current liabilities

2,525

2,300

-225

Total liabilities

4,993

4,157

-836

Total net assets

8,349

5,552

-2,797

Total liabilities and net assets

13,343

9,709

-3,634

©2021 SanBio Company Limited

4

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

SanBio Co. Ltd. published this content on 16 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 September 2021 09:01:01 UTC.


ę Publicnow 2021
All news about SANBIO COMPANY LIMITED
10/18SANBIO : Notice on Appointment of New Corporate Officer
PU
10/18Sanbio Company Limited Appoints Naoki Tsukahara as New Corporate Officer and Business H..
CI
10/14SANBIO : Announcement on Granting Stock Options (Share Acquisition Rights)
PU
09/22SanBio Records Non-Operating Income, Extraordinary Loss in H1
MT
09/21SANBIO : Notice on Recording of Non-Operating Income and Extraordinary Loss
PU
09/16SANBIO : Presentation for Financial Results for the 2nd Quarter of the Fiscal Year Ending ..
PU
09/14SANBIO : Consolidated Financial Results for the Six Months Ended July 31, 2021
PU
09/14SanBio Company Limited Announces Consolidated Earnings Results for the Six Months Ended..
CI
09/14SanBio Company Limited Provides Consolidated Earnings Guidance for the Fiscal Year Endi..
CI
09/14SANBIO : Notice Concerning Difference Between Consolidated Financial Forecasts and Actual ..
PU
More news
Financials
Sales 2022 - - -
Net income 2022 -5 497 M -48,2 M -48,2 M
Net cash 2022 17 541 M 154 M 154 M
P/E ratio 2022 -11,3x
Yield 2022 -
Capitalization 60 805 M 535 M 534 M
EV / Sales 2022 -
EV / Sales 2023 29,5x
Nbr of Employees 85
Free-Float 56,1%
Chart SANBIO COMPANY LIMITED
Duration : Period :
SanBio Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANBIO COMPANY LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Last Close Price 1 174,00 JPY
Average target price 2 660,00 JPY
Spread / Average Target 127%
EPS Revisions
Managers and Directors
Keita Mori President, CEO & Representative Director
Toru Kawanishi Chairman
Bijan Nejadnik Chief Medical Officer & Executive Officer
Chris sanbio Horan Chief Technical Operations Officer
Akihiro Tsujimura COO, Representative Director & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
SANBIO COMPANY LIMITED-12.19%535
GILEAD SCIENCES, INC.16.15%84 306
BIONTECH SE261.78%67 225
WUXI APPTEC CO., LTD.24.08%64 578
REGENERON PHARMACEUTICALS19.27%59 507
VERTEX PHARMACEUTICALS-21.73%47 610